Kalaris Therapeutics, Inc. KLRS 深 沪
等待开盘 08-14 09:30:00 美东时间
3.88
-0.060
-1.52%
华盛通- 最 高4.06
- 今 开3.92
- 成交量 5.65万股
- 最 低 3.84
- 昨 收 3.94
- 总市值 9231.40万
- 52周最高 11.88
- 市盈率 静 --
- 换手率 0.24%
- 52周最低 2.50
- 委 比 -60.40%
- 总股本 2379.23万
- 历史最高 1126.08
- 量 比 1.16
- 振 幅 5.58%
- 历史最低 3.03
- 每 手 1
- 风险率 2.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Kalaris Therapeutics Q2 EPS $(0.48) Beats $(0.49) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 21.31 percent increase over losses of $(0.61) per share from the same period last year.
08-11 20:03
Why Is Kalaris Therapeutics Stock Gaining Friday?
Kalaris Therapeutics, Inc. (NASDAQ:KLRS) announced expanded data from its Phase 1a single ascending dose trial evaluating TH103 for the treatment of neovascular age-related macular degeneration. Following the announcement, the stock jumped nearly 18%. The clinical-stage biopharmaceutical company sta...
07-18 01:31
Kalaris Therapeutics To Present Additional Data From Phase 1a Single Ascending Dose Trial Of TH103 In Neovascular Age-Related Macular Degeneration At ASRS Annual Meeting; On Track To Share Initial Data From Phase 1b/2 Study In H1 Of 2027
Data from the expanded cohorts reinforce the positive BCVA, OCT, pharmacokinetic and time-to-retreatment findings observed in the original cohorts Enrollment in the Phase 1b/2 multiple-ascending dose trial of TH103 continues, with preliminary data on track for 1H 2027 BERKELEY HEIGHTS, N.J., July 17...
07-17 19:02
TD Cowen Initiates Coverage On Kalaris Therapeutics with Buy Rating
TD Cowen analyst Tara Bancroft initiates coverage on Kalaris Therapeutics (NASDAQ:KLRS) with a Buy rating.
06-16 00:45
美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
Citizens Maintains Market Outperform on Kalaris Therapeutics, Lowers Price Target to $25
Citizens analyst Jonathan Wolleben maintains Kalaris Therapeutics (NASDAQ:KLRS) with a Market Outperform and lowers the price target from $26 to $25.
05-13 22:24
Kalaris Therapeutics Q1 EPS $(0.46) Beats $(0.53) Estimate
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(0.46) per share which beat the analyst consensus estimate of $(0.53) by 13.21 percent. This is a 81.75 percent increase over losses of $(2.52) per share
05-12 20:09
美股大行评级 | 美国银行、摩根士丹利、JB亨特运输服务、PNC金融服务、Cheniere Energy等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持FibroBiologics"买入"评级，目标价从4美元升至8美元；摩根士丹利：维持Ultragenyx药业"超配"评级，目标价从50美元升至67美元
04-17 11:27
Kalaris Therapeutics Launches Up To $100M At-The-Market Stock Offering Agreement With TD Cowen
Up to $100,000,000Kalaris Therapeutics, Inc.Common StockWe have entered into a sales agreement with TD Securities (USA) LLC, or TD Cowen, relating to the sale of shares of our common stock, par value $0.0001 per share,
04-14 04:22
